NewLink Genetics to Participate in Upcoming Investor Conference

AMES, Iowa, Nov. 27, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ: NLNK) will participate in the Global Mizuho Investor Conference on Tuesday, December 5th, in New York City.  The format of the conference is one-on-one meetings with investors only. 

About NewLink Genetics Corporation

NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.  NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer.  Indoximod is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies.  For more information, visit www.newlinkgenetics.com, and follow us on Twitter @NLNKGenetics.

Investor Contact:Lisa MillerDirector of Investor RelationsNewLink Genetics(515) 598-2555[email protected]

Media Contact:Vivian NiPublic & Media RelationsLaVoieHealthScience617-374-8800, ext. 109[email protected]

Source: NewLink Genetics Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• RedStone Prices FalconX’s $170M+ of Credit on Pareto, Bringing Institutional Prime Brokerage Credit To New Chains
• Australia Considers Requiring Social Media to Have Algorithm Opt-In Feature for Users
• Rising Treasury Yields Put Recent Bitcoin Rally Under Pressure